Log in
Opioid antidiarrheal

Loperamide

Loperamide is a synthetic opioid agonist used primarily to treat acute and chronic diarrhea by decreasing intestinal motility and fluid secretion. It acts on μ-opioid receptors in the myenteric plexus of the gut. The most testable fact: loperamide does not cross the blood-brain barrier at therapeutic doses due to P-glycoprotein efflux, preventing CNS opioid effects.

Practice questionsHigh-yield facts
Drug classSynthetic opioid antidiarrheal (μ-opioid receptor agonist)
MechanismActivates intestinal μ-opioid receptors, reduces peristalsis and secretion
Main usesAcute diarrhea, chronic diarrhea, traveler's diarrhea
Key adverse effectConstipation, toxic megacolon in infectious colitis
6 min readFor medical studentsUpdated 2026-10-14

Mechanism of action

Loperamide is a synthetic phenylpiperidine opioid that selectively activates μ-opioid receptors in the myenteric plexus of the intestinal wall. This activation produces several antidiarrheal effects:

  • Decreased peristalsis: Slows propulsive gut motility by inhibiting acetylcholine and prostaglandin release from enteric neurons
  • Increased intestinal transit time: Allows more time for water and electrolyte absorption
  • Reduced intestinal secretion: Decreases fluid secretion into the lumen
  • Increased anal sphincter tone: Improves fecal continence

The critical pharmacological feature is that loperamide is a substrate for P-glycoprotein (MDR1 efflux pump) at the blood-brain barrier. At therapeutic doses, P-glycoprotein actively pumps loperamide out of the CNS, preventing opioid effects such as analgesia, euphoria, or respiratory depression. This makes it safe for over-the-counter use. However, at supratherapeutic doses or when P-glycoprotein is inhibited (by drugs like quinidine or verapamil), CNS penetration can occur, leading to opioid toxicity and dangerous cardiac effects including QT prolongation.

High-yield for exams
  • Loperamide is a μ-opioid agonist that does not cross the blood-brain barrier due to P-glycoprotein efflux at therapeutic doses.
  • Contraindicated in acute dysentery, C. difficile colitis, and acute ulcerative colitis due to risk of toxic megacolon.
  • FDA Black Box Warning: at supratherapeutic doses (abuse), loperamide causes QT prolongation, torsades de pointes, and cardiac arrest.
  • P-glycoprotein inhibitors (quinidine, ritonavir) increase CNS penetration and risk of opioid toxicity.
  • First-line symptomatic treatment for acute nonspecific diarrhea; does not treat underlying cause.
  • CYP3A4 substrate: interactions with azole antifungals and macrolides increase systemic exposure.
  • Should not be used in children under 2 years due to risk of CNS depression and ileus.
  • Toxic megacolon is the classic serious complication when used inappropriately in infectious or inflammatory colitis.

Indications

Loperamide is indicated for:

  • Acute nonspecific diarrhea: First-line symptomatic treatment in adults and children over 2 years
  • Chronic diarrhea: Associated with inflammatory bowel disease (IBD), irritable bowel syndrome with diarrhea (IBS-D), or short bowel syndrome
  • Traveler's diarrhea: Adjunct to antibiotics in mild to moderate bacterial enteritis
  • Ileostomy output reduction: Decreases high-output ileostomy discharge

Important limitations

Loperamide provides symptomatic relief only and does not treat the underlying cause of diarrhea. It should not be used as primary therapy in:

  • Acute dysentery (bloody diarrhea with fever)
  • Pseudomembranous colitis (Clostridioides difficile)
  • Acute ulcerative colitis flares
  • Bacterial enterocolitis caused by invasive organisms (Salmonella, Shigella, Campylobacter)

In these conditions, slowing motility can worsen disease by prolonging mucosal contact with toxins or pathogens and increasing the risk of toxic megacolon.

Pharmacokinetics

  • Absorption: Well absorbed from the GI tract; undergoes extensive first-pass metabolism
  • Bioavailability: Very low (~0.3%) due to hepatic first-pass effect and intestinal P-glycoprotein efflux
  • Distribution: Highly lipophilic but does not cross the blood-brain barrier at therapeutic doses because of active P-glycoprotein efflux
  • Metabolism: Extensively metabolized in the liver via CYP3A4 and CYP2C8 to inactive metabolites
  • Excretion: Primarily fecal (via bile); minimal renal elimination
  • Half-life: 9-14 hours, but antidiarrheal effect lasts 4-6 hours due to slow dissociation from gut opioid receptors

Clinical relevance: Because loperamide is a CYP3A4 substrate and P-glycoprotein substrate, drugs that inhibit these systems can increase systemic exposure and CNS penetration, raising the risk of toxicity.

Adverse effects

At therapeutic doses, loperamide is generally well tolerated. Common adverse effects include:

  • Constipation: Most frequent; dose-related
  • Abdominal cramping or bloating
  • Nausea
  • Dizziness or drowsiness: Rare at standard doses
  • Dry mouth

Serious adverse effects

  • Toxic megacolon: Life-threatening complication when used in acute ulcerative colitis, C. difficile colitis, or bacterial dysentery; results from excessive colonic distension and risk of perforation
  • Paralytic ileus: Intestinal obstruction from severe hypomotility
  • Cardiac toxicity: With supratherapeutic doses (abuse), loperamide can cause QT prolongation, torsades de pointes, ventricular arrhythmias, syncope, and cardiac arrest
  • CNS opioid effects: At very high doses or with P-glycoprotein inhibitors, respiratory depression and altered mental status can occur

Abuse potential: Loperamide has been misused at extremely high doses (100-400 mg, vs. therapeutic 2-4 mg) to achieve opioid euphoria or self-treat opioid withdrawal. This has led to fatal cardiac arrhythmias and prompted FDA warnings.

Hypersensitivity

Rare allergic reactions including rash, urticaria, and angioedema have been reported.

Contraindications and warnings

Absolute contraindications

  • Acute dysentery (bloody diarrhea with fever)
  • Acute ulcerative colitis or flare
  • Clostridioides difficile colitis or pseudomembranous colitis
  • Bacterial enterocolitis caused by invasive organisms
  • Paralytic ileus or intestinal obstruction
  • Hypersensitivity to loperamide
  • Children under 2 years: Risk of CNS depression, ileus, and toxicity

FDA Black Box Warning

Cardiac risks with higher-than-recommended doses: The FDA has issued a Black Box Warning for loperamide regarding serious cardiac adverse events including QT prolongation, torsades de pointes, other ventricular arrhythmias, cardiac arrest, syncope, and death. These events have been reported with loperamide abuse and misuse, particularly when taken at doses higher than recommended. Patients should be counseled to use only the recommended dose and never exceed it. Healthcare providers should be aware of this risk, especially in patients with a history of substance abuse or those attempting to self-treat opioid withdrawal.

Warnings and precautions

  • Hepatic impairment: Reduced first-pass metabolism may increase systemic exposure; use with caution
  • Abdominal distension: Discontinue if abdominal distension develops in acute colitis
  • Dehydration risk: Does not replace fluid and electrolyte repletion; always address hydration
  • AIDS patients with diarrhea: Increased risk of toxic megacolon; use cautiously
  • Pregnancy category C: Limited human data; use only if benefit outweighs risk
  • Breastfeeding: Small amounts excreted in breast milk; generally considered compatible but use caution
  • QT prolongation: Risk increases with supratherapeutic doses or drug interactions; avoid in patients with long QT syndrome or structural heart disease when using high doses

Abuse deterrence

Patients should be counseled that exceeding recommended doses is dangerous and can be fatal.

Drug interactions

P-glycoprotein inhibitors

Drugs that inhibit P-glycoprotein can increase CNS penetration of loperamide:

  • Quinidine
  • Ritonavir and other protease inhibitors
  • Verapamil, diltiazem
  • Cyclosporine
  • Itraconazole, ketoconazole

Combination may lead to opioid CNS effects including respiratory depression.

CYP3A4 inhibitors

Inhibitors of CYP3A4 increase loperamide plasma levels:

  • Macrolide antibiotics (erythromycin, clarithromycin)
  • Azole antifungals (ketoconazole, itraconazole)
  • Protease inhibitors
  • Grapefruit juice

Increased systemic exposure raises risk of cardiac and CNS toxicity.

CYP3A4 inducers

Inducers may reduce loperamide efficacy by increasing metabolism:

  • Rifampin
  • Phenytoin, carbamazepine
  • St. John's wort

Additive CNS depression

Combining loperamide with other CNS depressants (benzodiazepines, alcohol, opioids) may enhance sedation, especially at high doses.

Serotonergic agents

No significant interaction, but caution is advised when combining with other agents that affect gut motility.

Clinical pearls

  • P-glycoprotein is key: Loperamide's safety as an OTC drug depends on P-glycoprotein keeping it out of the brain. Inhibition of this transporter converts a safe antidiarrheal into a CNS opioid.
  • Do not use in bloody diarrhea: If a patient has fever and bloody stools, think invasive bacterial infection or IBD flare—loperamide is contraindicated and can cause toxic megacolon.
  • Not for C. difficile: Slowing colonic transit in C. difficile infection worsens toxin exposure and increases complications.
  • Rehydration first: Loperamide slows diarrhea but does not replace lost fluids. Oral or IV rehydration is essential, especially in children and the elderly.
  • Cardiac risk with abuse: Loperamide cardiotoxicity (QT prolongation, ventricular arrhythmias) is an emerging concern with opioid epidemic-related misuse. Suspect in young patients with syncope or arrhythmia and a history of opioid use disorder. The FDA Black Box Warning specifically addresses this risk.
  • Traveler's diarrhea adjunct: Loperamide can be combined with antibiotics (fluoroquinolones, azithromycin) in traveler's diarrhea for faster symptom relief, but should be stopped if dysentery develops.
  • Ileostomy patients: Useful for reducing high-output ileostomy, improving quality of life and reducing dehydration risk.
  • Exam trap: A vignette presenting acute bloody diarrhea with fever in a patient taking loperamide is testing whether you recognize the contraindication and risk of toxic megacolon.
  • Not a controlled substance: Despite being an opioid agonist, loperamide is not scheduled under the Controlled Substances Act due to lack of CNS activity at therapeutic doses.
Mnemonic

LOPE for Loperamide contraindications: Liver caution, Obstruction/ileus, Pseudomembranous colitis, Enterocolitis (invasive bacterial/bloody diarrhea).

Practice questions

1. A 28-year-old man presents with 3 days of watery diarrhea, abdominal cramps, and low-grade fever after returning from a camping trip. He took loperamide for symptom relief. Today, he develops high fever (39.5°C), severe abdominal pain, and bloody diarrhea. Examination reveals abdominal distension and tenderness. Stool culture grows Shigella. What is the most likely complication of his loperamide use?

Answer: B. Toxic megacolon is a life-threatening complication of using loperamide in invasive bacterial enterocolitis (such as Shigella) or inflammatory bowel disease. Slowing colonic motility allows prolonged mucosal exposure to bacterial toxins and increases risk of colonic distension and perforation. Loperamide is contraindicated in acute dysentery (bloody diarrhea with fever). Respiratory depression and QT prolongation occur with supratherapeutic doses, not therapeutic use. Hepatic encephalopathy and ATN are unrelated to loperamide in this context.

2. A 35-year-old woman with HIV and chronic diarrhea takes loperamide daily for symptom control. She is also taking ritonavir as part of her antiretroviral regimen. Over the past week, she has developed increasing drowsiness, confusion, and pinpoint pupils. Vital signs show respiratory rate of 8/min. What is the most likely explanation for her presentation?

Answer: C. Ritonavir is a potent inhibitor of both CYP3A4 and P-glycoprotein. P-glycoprotein normally effluxes loperamide from the CNS, preventing opioid effects. When P-glycoprotein is inhibited, loperamide can cross the blood-brain barrier and cause CNS opioid toxicity, including respiratory depression, miosis, and altered mental status. The clinical picture of opioid toxicity (pinpoint pupils, respiratory depression) points to increased CNS loperamide exposure rather than other causes. This is a classic drug interaction tested on exams.

3. A 45-year-old man with irritable bowel syndrome with diarrhea is started on loperamide for symptom management. Two weeks later, he is brought to the emergency department with syncope. ECG shows QT interval of 620 ms and polymorphic ventricular tachycardia. Toxicology screen is negative for traditional opioids. Further history reveals he has been taking 50-60 tablets of loperamide daily. What is the mechanism of his cardiac toxicity?

Answer: B. At supratherapeutic doses, loperamide blocks cardiac potassium channels (particularly hERG/IKr), leading to QT prolongation and risk of torsades de pointes. Loperamide abuse has become a recognized cause of sudden cardiac death in patients with opioid use disorder attempting to self-treat withdrawal or achieve euphoria. The mechanism is direct cardiac ion channel blockade, not ischemia, electrolyte disturbance, or vagal effects. This emerging toxicity pattern is increasingly tested on exams.

Frequently asked questions

How does loperamide work?

Loperamide works by activating μ-opioid receptors in the gut wall, which slows intestinal peristalsis, increases transit time, and reduces fluid secretion. This allows more time for water and electrolyte absorption, reducing stool frequency and improving consistency. Unlike other opioids, it does not cross the blood-brain barrier at therapeutic doses due to active efflux by P-glycoprotein, so it lacks central analgesic or euphoric effects.

What are the side effects of loperamide?

The most common side effects of loperamide are constipation, abdominal cramping, bloating, and nausea. Serious adverse effects include toxic megacolon (when used in acute colitis or invasive bacterial diarrhea), paralytic ileus, and cardiac toxicity such as QT prolongation and ventricular arrhythmias at very high doses. CNS opioid effects like respiratory depression can occur with abuse or when combined with P-glycoprotein inhibitors.

Is loperamide a controlled substance?

No, loperamide is not a controlled substance under the DEA scheduling system. Although it is a synthetic opioid agonist, it does not produce CNS opioid effects at therapeutic doses because P-glycoprotein prevents it from crossing the blood-brain barrier. This makes it safe for over-the-counter use. However, abuse at very high doses can cause opioid-like effects and serious cardiac toxicity.

When should you not use loperamide?

Loperamide should not be used in acute dysentery (bloody diarrhea with fever), Clostridioides difficile colitis, acute ulcerative colitis, or bacterial enterocolitis caused by invasive organisms like Salmonella or Shigella. In these conditions, slowing gut motility can worsen disease by prolonging toxin or pathogen exposure and increasing the risk of toxic megacolon. It is also contraindicated in children under 2 years and in patients with paralytic ileus or intestinal obstruction.

Loperamide vs diphenoxylate — what is the difference?

Both are opioid antidiarrheals that slow intestinal motility, but loperamide does not cross the blood-brain barrier at therapeutic doses, while diphenoxylate has some CNS penetration and is combined with atropine (as Lomotil) to discourage abuse. Diphenoxylate is a Schedule V controlled substance, whereas loperamide is not controlled. Loperamide is preferred for most patients due to better safety profile, fewer CNS effects, and over-the-counter availability.

Conditions it is used for

Acute diarrheaChronic diarrheaTraveler's diarrheaIrritable bowel syndrome with diarrheaInflammatory bowel disease (symptomatic)High-output ileostomyShort bowel syndrome
DiphenoxylateAtropineBismuth subsalicylateOctreotideEluxadolineRifaximinCholestyramineAlosetron

Sources and further reading

DailyMed (FDA labels)StatPearls (NCBI Bookshelf)MedlinePlusWHO ATC/DDD index: A07DA03

Educational content for medical students, prepared by the WhiteCoat Pro editorial team with AI assistance; every page is reviewed by a second AI model for factual errors. It is not medical advice and does not replace the product label, local guidelines or a clinician.